초록 ▼

1. 다양한 조직에서 신경줄기세포의 추출 및 연구
인태아 중뇌와 선조체에서 유래한 신경전구 세포를 추출함.
선조체 유래 신경전구세포에서 세포 특성비교 가능함.
인태반 유래 줄기세포를 추출함.
2. 다량의 신경분화 및 증식법 연구
small compound에 의한 신경전구세포 증식능 유지및 효율을 높임.
CD13+ cell population을 증가시키는 세로운 성장인자 확보함.
3. 신경줄기세포들에서의 분비단백질의 분석연구 및 항염증 효능 평가
사람유래 신경전구세포와 인태반줄기세포에서 분비

1. 다양한 조직에서 신경줄기세포의 추출 및 연구
인태아 중뇌와 선조체에서 유래한 신경전구 세포를 추출함.
선조체 유래 신경전구세포에서 세포 특성비교 가능함.
인태반 유래 줄기세포를 추출함.
2. 다량의 신경분화 및 증식법 연구
small compound에 의한 신경전구세포 증식능 유지및 효율을 높임.
CD13+ cell population을 증가시키는 세로운 성장인자 확보함.
3. 신경줄기세포들에서의 분비단백질의 분석연구 및 항염증 효능 평가
사람유래 신경전구세포와 인태반줄기세포에서 분비되는 cytokines 프로파일링 함.
사람유래 신경전구세포와 인태반줄기세포에서 분비되는 성장인자 (growth factor) 비교함.
4. FoxA2 유전자 도입된 신경줄기세포라인 구축
human 선조체에서 Foxa2 발현에 의한 TH+ cell 증가됨.
human foxa2 유전자 확보함.
human Foxa2 AAV delivery system 제작함.
선조체 유래 신경전구세포에서도 TH+ cell 분화가능함.
4. FoxA2 의 신경 분화 관련 fuctional genomics 연구
bioinformatics analysis (oppusum, human Genome search)에 의한 foxa2 binding site 분석함.
microarray analysis에 의한 foxa2 과발현시 유전자발현 양상 분석함.
5. 전임상실험을 위한 다계통위축증 신경질환 확립 및 효능 평가
6-OHDA와 QA를 이용한 다계통 위축증 쥐모델 구축함.
다계층위축증의 유발주요인자인 alpha-synuclein의 adenoviral delivery system 확보함.
Acute 다계통위축-파킨슨증 마우스 모델 제작 가능함. (alpha-synuclein의 adenoviral delivery system과 3-NP를 이용함. )

Abstract ▼

1. Purpose
Human fetal neural precursor cells (hfNPCs) transplantation has been considered as an alternative therapy for medicine resistant Parkinson-like symptom as multiple system atrophy (MSA-P). In this study, the model of 6-hydroxydopamine(6-OHDA) and quinolinic acid (QA)-induced rat used an

1. Purpose
Human fetal neural precursor cells (hfNPCs) transplantation has been considered as an alternative therapy for medicine resistant Parkinson-like symptom as multiple system atrophy (MSA-P). In this study, the model of 6-hydroxydopamine(6-OHDA) and quinolinic acid (QA)-induced rat used and then investigated on the effects of grafted Foxa2-hfNPCs by inspecting whether the transplantation of foxa2-hfNPCs contributed to preventing cells survivality through the inhibition of microglia and astrocyte activation and pro-inflammatory factor. We do establishment of in vivo PoC using FoxA2-overexpressing human neural stem cell lines in Multiple System Atrophy : Safety and Efficacy
2. Introduction
For more than two decades cell repair has been considered an important therapeutic option in Parkinson disorders.However, despite partial functional benefit and long-term survival, recent evidence of Lewy body (LB) pathology in grafted fetal midbrain neurons in Parkinson's disease (PD) patients suggests that grafted cells may become affected by the disease process in the host brain. MSA is another neurodegen- erative disease with prominent α -synuclein pathology that presents with parkinsonism in 60% to 80% of MSA cases (MSA-P) However, in light of a recently reported possibility of host-to-graft disease propagation in PD. the question remains whether glial α -synucleinopathy of MSA type may affect embryonic striatal grafts placed into a diseased host striatum.
3. Results
- Isolation and characterization of human derived Neural precour cells and human placenta stem cells
- development of large scale proliferation system and differentiation system into neuron, astrocyte and oligodendrocytes from the human derived Neural precour cells
- Development and Chracterization of Foxa2-expressed NPCs cell lines.
- Establishment of in vivo efficacy study using FoxA2-overexpressing human neural stem cell lines in Multiple System Atrophy
- novel cell death mechanism through CHOP and AIMP2-related ER stress in the treatment of neurotoxins for MSA and PD animal model
4. Application
Our data suggest that the presence of MSA-like α -synuclein-related autophagic cell death and related to it pro-inflammatory microenvironment may compromise the connectivity and neurorestora- tive outcome of striatal grafts.